A Study Comparing Doxycycline and Levofloxacin for Treating COPD Exacerbations (DOLE-COPD)

Amina Aslam

Status: Not yet enrolling

Conditions: COPD

Treatments: Drug: Levofloxacin; Drug: Doxycycline

Study type: Interventional

Funder types: Other

Identifiers

NCT06915688

LGH-COPD-2025

Details and patient eligibility

About

This study will include patients with chronic obstructive pulmonary disease (COPD) who present with an acute exacerbation. Participants will be randomly assigned to receive either doxycycline or levofloxacin for 5 days. The aim is to compare how effective each antibiotic is in improving symptoms after 2 days of treatment.

Full description

This randomized controlled trial will evaluate the effectiveness of two antibiotics-doxycycline (a tetracycline) and levofloxacin (a fluoroquinolone)-in the treatment of acute exacerbations of chronic obstructive pulmonary disease. Participants will be assigned to one of the two treatment groups and will receive either doxycycline 100 mg twice daily or levofloxacin 500 mg once daily for 5 days. The primary outcome is clinical cure. This will be evaluated 2 days after completion of antibiotic therapy, based on symptom resolution and laboratory markers.

Enrollment: 188 estimated patients

Sex: All

Ages: 40 to 70 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• diagnosed cases of COPD Exacerbation of COPD Able to provide Written consent No anti biotic taken with in past 4 weeks

Exclusion criteria

• hypersensitivity to any drugs Pneumonia evidence on xray/ hrct chest Any other pulmonary condition e.g asthma Pregnancy/breast feeding Taking treatment for other active infections

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

188 participants in 2 patient groups

Arm 1

Active Comparator group

Description:

Doxycycline will be given to this group

Treatment:

Drug: Doxycycline

Arm 2

Active Comparator group

Description:

Levofloxacin in copd patients

Treatment:

Drug: Levofloxacin